ANKTIVA Shows Promise in Lung Cancer Treatment
ImmunityBio's (IBRX) ANKTIVA demonstrates improved immune response and survival in non-small cell lung cancer patients when combined with checkpoint inhibitors.
NOTRELOAD AI
Meta Faces the Biggest Hit From Rising Data Center Energy Costs
Meta faces growing pressure as tech giants are asked to cover their own data center energy costs, making AI investments more expensive and risky for investors.
Evercore ISI Starts Coverage on Reddit with Bullish Outlook
Evercore ISI initiates coverage on Reddit with an Outperform rating and $320 price target, citing strong growth, improving monetization, and rising ad potential.
Goldman Sachs Starts Coverage on Super Micro With a Sell Rating
Goldman Sachs initiates coverage on Super Micro with a Sell rating, citing margin pressure, rising competition, and limited profit visibility despite AI leadership.
Travere Therapeutics Stock Plunges on FDA Approval Uncertainty
Travere Therapeutics shares drop 33% in premarket as FDA requests more data for FILSPARI FSGS approval, delaying potential first-ever treatment for rare kidney disease.
BofA Raises Biohaven Price Target to $15 on Pipeline Progress, But Stays Cautious
Bank of America upgrades Biohaven's price target by 50% following positive pipeline updates, but maintains neutral rating citing uncertain 2026 catalysts.